Discover
NUVB
Nuvation Bio Inc.
6.43
35 x 6.00
1 x 6.97
bid
ask
+
0.17
2.72%
100 @ 04:00 PM
6.34 -0.09 (1.40%)
| Ytd | -28.24% | |
| 1y | 173.62% |
6.15
day range
6.63
2.18
52 week range
9.75
| Open | 6.33 | Prev Close | 6.26 | Low | 6.15 | High | 6.63 | Mkt Cap | 2.23B |
| Vol | 7.42M | Avg Vol | 6.26M | EPS | -0.43 | P/E | -14.95 | Forward P/E | -96.83 |
| Beta | 1.52 | Short Ratio | 6.59 | Inst. Own | 64.87% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-04 | 50-d Avg | 5.24 | 200-d Avg | 5.59 | 1yr Est | 12.33 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-08-06 | 2026-06 | -0.15 | N/A | N/A | N/A |
| 2026-05-04 | 2026-03 | -0.03 | 0.01 | 0.04 | 135.66% |
| 2026-03-02 | 2025-12 | -0.11 | -0.11 | N/A | N/A |
| 2025-11-03 | 2025-09 | -0.17 | -0.16 | 0.01 | 5.88% |
| 2025-08-07 | 2025-06 | -0.17 | -0.17 | N/A | N/A |
| 2025-05-07 | 2025-03 | -0.16 | -0.16 | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-07-07 | RBC Capital | Upgrade | Outperform | Outperform |
| 2026-07-07 | Truist Securities | Upgrade | Buy | Buy |
| 2026-05-05 | RBC Capital | Upgrade | Outperform | Outperform |
| 2026-05-05 | Wedbush | Upgrade | Outperform | Outperform |
| 2026-05-05 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2026-04-16 | Wedbush | Upgrade | Outperform | Outperform |
Profile
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headquartered in New York, New York.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-09-03 | CUI XIANGMIN | Director | 0.00 | Conversion of Exercise of derivative security |
| 2025-11-18 | HANLEY DAVID C | Chief Technology Officer | 24.00K | Sale |
| 2025-06-15 | HUNG DAVID T | Chief Executive Officer | 59.28M | Purchase |
| 2026-04-16 | LIU DONGFANG | Officer | 18.00K | Sale |
| 2026-02-26 | MAKUNJE MOSES | Officer | 68.14K | Stock Award(Grant) |
| 2026-06-22 | MARKEL STACY | Officer | 32.59K | Sale |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | FMR, LLC | 51.99M | 302.06M | 14.93% |
| 2026-03-30 | Decheng Capital LLC | 25.95M | 150.80M | 7.45% |
| 2026-03-30 | Blackrock Inc. | 25.10M | 145.83M | 7.21% |
| 2026-03-30 | Vanguard Capital Management LLC | 11.63M | 67.55M | 3.34% |
| 2026-03-30 | Omega Fund Management, Llc | 8.08M | 46.95M | 2.32% |
| 2026-03-30 | Laurion Capital Management, LP | 7.82M | 45.45M | 2.25% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-05-30 | Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 17.54M | 101.89M | 5.04% |
| 2026-03-30 | VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 8.66M | 50.29M | 2.49% |
| 2026-05-30 | iShares Trust-iShares Russell 2000 ETF | 5.72M | 33.25M | 1.64% |
| 2026-05-30 | Fidelity Mt. Vernon Street Trust-Fidelity Growth Company K6 Fund | 4.91M | 28.53M | 1.41% |
| 2026-05-30 | Fidelity Mt. Vernon Street Trust-Fidelity Series Growth Company Fund | 4.52M | 26.24M | 1.30% |
| 2026-03-30 | VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 2.66M | 15.44M | 0.76% |